JP2015513557A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513557A5
JP2015513557A5 JP2014561064A JP2014561064A JP2015513557A5 JP 2015513557 A5 JP2015513557 A5 JP 2015513557A5 JP 2014561064 A JP2014561064 A JP 2014561064A JP 2014561064 A JP2014561064 A JP 2014561064A JP 2015513557 A5 JP2015513557 A5 JP 2015513557A5
Authority
JP
Japan
Prior art keywords
agent according
therapeutic agent
pain
peripheral neuropathy
neuropathic pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014561064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029258 external-priority patent/WO2013134336A2/en
Publication of JP2015513557A publication Critical patent/JP2015513557A/ja
Publication of JP2015513557A5 publication Critical patent/JP2015513557A5/ja
Pending legal-status Critical Current

Links

JP2014561064A 2012-03-09 2013-03-06 疼痛の治療に対するアダプター関連キナーゼ1の阻害 Pending JP2015513557A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608849P 2012-03-09 2012-03-09
US61/608,849 2012-03-09
PCT/US2013/029258 WO2013134336A2 (en) 2012-03-09 2013-03-06 Inhibition of adaptor associated kinase 1 for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2015513557A JP2015513557A (ja) 2015-05-14
JP2015513557A5 true JP2015513557A5 (enExample) 2016-04-21

Family

ID=47884616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561064A Pending JP2015513557A (ja) 2012-03-09 2013-03-06 疼痛の治療に対するアダプター関連キナーゼ1の阻害

Country Status (14)

Country Link
US (4) US20140080834A1 (enExample)
EP (2) EP2822555B1 (enExample)
JP (1) JP2015513557A (enExample)
CN (1) CN104220071A (enExample)
AU (1) AU2013230066A1 (enExample)
CA (1) CA2866145A1 (enExample)
DK (1) DK2822555T3 (enExample)
ES (1) ES2657061T3 (enExample)
HK (1) HK1199814A1 (enExample)
HU (1) HUE036040T2 (enExample)
NO (1) NO2935475T3 (enExample)
PL (1) PL2822555T3 (enExample)
PT (1) PT2822555T (enExample)
WO (1) WO2013134336A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102085121B1 (ko) * 2012-03-09 2020-03-05 렉시컨 파마슈티컬스 인코퍼레이티드 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
RU2014140735A (ru) * 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US9708337B2 (en) 2013-02-22 2017-07-18 Bristol-Myers Squibb Company Aryl amide-based kinase inhibitors
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
CN105492444B (zh) * 2013-07-02 2018-09-07 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
EP3019475A1 (en) 2013-07-08 2016-05-18 Bristol-Myers Squibb Company Aryl amide kinase inhibitors
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法
EP3044226B1 (en) * 2013-09-11 2017-09-06 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
ES2678877T3 (es) * 2013-10-11 2018-08-20 Bristol-Myers Squibb Company Inhibidores de pirrolotriazina quinasa
MX2016009352A (es) * 2014-01-31 2016-10-13 Bristol Myers Squibb Co Inhibidores de quinasa a base de quinolina.
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法
KR102379518B1 (ko) 2014-04-02 2022-03-25 브리스톨-마이어스 스큅 컴퍼니 비아릴 키나제 억제제
JP2017523214A (ja) * 2014-08-05 2017-08-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環キナーゼ阻害剤
KR102662215B1 (ko) 2014-11-06 2024-05-02 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도
WO2016164295A2 (en) 2015-04-10 2016-10-13 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
WO2017059085A1 (en) 2015-10-01 2017-04-06 Bristol-Myers Squibb Company Biaryl kinase inhibitors
US10246469B2 (en) 2015-10-01 2019-04-02 Bristol-Myers Squibb Company Biaryl kinase inhibitors
WO2017176961A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
US11192892B2 (en) 2016-04-06 2021-12-07 Bial—R&D Investments, S.A. Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
KR102590444B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
KR102590438B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
WO2023196584A2 (en) * 2022-04-08 2023-10-12 New York University Endocytosis inhibitors and their use for pain treatment
WO2025225608A1 (en) * 2024-04-23 2025-10-30 Otsuka Pharmaceutical Co., Ltd. Tetrahydropyrazolopyridine derivative

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
CA2667962A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2009140128A2 (en) * 2008-05-13 2009-11-19 Irm Llc Compounds and compositions as kinase inhibitors
WO2010028005A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules

Similar Documents

Publication Publication Date Title
JP2015513557A5 (enExample)
JP2015503422A5 (enExample)
JP2017506627A5 (enExample)
JP2016028092A5 (enExample)
JP2016065085A5 (enExample)
JP2015528502A5 (enExample)
CN109843873A (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
JP2014530840A5 (enExample)
EP2953624A4 (en) METHOD FOR THE TREATMENT OF MICROBIAL INFECTIONS, INCLUDING MASTITIS
JP2016139345A5 (enExample)
SI3066085T1 (sl) Postopek sinteze inhibitorja indolamina 2,3-dioksigenaze
EP3307738A4 (en) ARYL-DIHYDRO-2H-BENZO [B] [1,4] OXAZINE-SULPHONAMIDE AND RELATED COMPOUNDS FOR USE AS AGENTS OF RORY AND FOR THE TREATMENT OF DISEASES
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP3292119A4 (en) DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
JP2015016294A5 (enExample)
JP2017531686A5 (enExample)
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201692518A2 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
BR112014017493A2 (pt) usos terapêuticos
JP2015005289A5 (enExample)
WO2014180882A3 (en) Treatment of brain metastasis from cancer
ES2525079A1 (es) Actividad antiparasitaria de escuaramidas
IL260009B (en) Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
LT3148588T (lt) N,n-bis-2-merkaptoetilizoftalamidas, skirtas parkinsono ligos gydymui
ICHIE The Beginning of Music & Acoustical Medicine